C94.2 Acute megakaryoblastic leukemia

Name of the Condition

• Acute megakaryoblastic leukemia
• ICD-10 Code: C94.2

Summary

Acute megakaryoblastic leukemia is a rare subtype of acute myeloid leukemia (AML) characterized by the rapid proliferation of immature megakaryoblasts (precursor cells of platelets) in the bone marrow. This condition disrupts normal blood cell production, leading to thrombocytopenia, anemia, and neutropenia. It is classified as a high-grade malignancy with aggressive clinical behavior and is more common in children, particularly those with Down syndrome.

Causes

The exact cause involves genetic mutations or chromosomal abnormalities in hematopoietic stem cells, leading to uncontrolled proliferation of megakaryoblasts. Contributing factors may include prior exposure to chemotherapy or radiation, genetic predispositions, or underlying myelodysplastic syndromes.

Risk Factors

• Prior exposure to chemotherapy or radiation
• History of myelodysplastic syndromes
• Certain genetic syndromes (e.g., Down syndrome)
• Advanced age
• Male gender
• Exposure to benzene or other toxic chemicals

Symptoms

• Severe fatigue or weakness
• Unexplained weight loss
• Fever or recurrent infections
• Easy bruising or bleeding
• Shortness of breath
• Pale skin (pallor)
• Enlarged liver or spleen (hepatosplenomegaly)

Diagnosis

Diagnosis involves a physical examination, followed by blood tests (complete blood count, peripheral smear) to identify abnormal megakaryoblasts. Bone marrow aspiration and biopsy are performed to confirm the presence of malignant cells and assess blast percentage. Cytogenetic and molecular testing may be used to identify specific genetic abnormalities.

Treatment Options

Treatment typically involves intensive chemotherapy to induce remission, followed by consolidation therapy. Allogeneic stem cell transplantation may be considered for eligible patients, especially those with high-risk features. Supportive care, including blood transfusions and infection prevention, is essential during treatment.

Prognosis and Follow-Up

Prognosis varies based on age, genetic profile, and response to therapy. Children with Down syndrome often have better outcomes. Regular follow-up with blood counts, bone marrow assessments, and monitoring for relapse is critical. Long-term survival depends on achieving and maintaining remission.

Complications

• Severe bleeding due to thrombocytopenia
• Life-threatening infections from neutropenia
• Anemia-related fatigue and organ dysfunction
• Potential for leukemic transformation or relapse
• Treatment-related toxicities (e.g., organ damage, secondary malignancies)

Lifestyle & Prevention

• Avoid exposure to known carcinogens (e.g., benzene)
• Maintain a balanced diet and regular exercise to support overall health
• Practice good hygiene to reduce infection risk
• Follow recommended cancer screening guidelines if at increased risk
• Discuss genetic counseling if a hereditary syndrome is suspected

When to Seek Professional Help

Seek immediate medical attention for unexplained bleeding, high fever, severe fatigue, or signs of infection. Persistent symptoms like unexplained weight loss, bruising, or shortness of breath should prompt evaluation by a healthcare provider.

Tips for Medical Coders

When coding for acute megakaryoblastic leukemia (C94.2), ensure documentation specifies the subtype and confirms the diagnosis through laboratory or pathology reports. Note the patient’s age and any associated genetic conditions (e.g., Down syndrome) as these may impact coding specificity. Verify that the code aligns with the clinical presentation and avoid using this code for non-megakaryoblastic leukemias.